dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma

This study intends to evaluate the efficacy and safety of drug-eluting transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (dTACE-HAIC) plus Bevacizumab and Atezolizumab for patients with intermediate-advanced huge hepatocellular carcinoma.

Trial Details

NCT ID
NCT06609863
Phase
NA
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • dTACE-HAIC
Locations (sample)
  • Beijing, None Selected, China|39.9075,116.39723

Key Eligibility Criteria

  • Clinical diagnosis of HCC.
  • Age between 18 and 75 years;
  • The maximum tumor size ≥10 cm;
  • Intermediate-advanced huge HCC, advanced HCC with PVTT type I-III

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →